

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form 8-K

RENHUANG PHARMACEUTICALS INC
Form 8-K
February 06, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 29, 2007

Renhuang Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Nevada
(State or Other Jurisdiction of Incorporation)

0-24512 88-1273503
(Commission File Number) (IRS Employer Identification Number)

No. 281, Taiping Road, Taiping District,
Harbin, Heilongjiang Province, 150050
P. R. China
(Address of Principal Executive Offices)

+86-451-5762-0378
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form 8-K

On January 29, 2007, Renhuang Pharmaceuticals, Inc (the "Company") issued a press release announcing a RMB 18 million (US\$ 2.3 million) order from Sichuan Hongji Pharmaceutical Co. Ltd., which is a major pharmaceutical distribution company in China. A copy of the press release is attached as Exhibit 99.1 to this report and is being furnished to the SEC and shall not be deemed "filed" for any purpose.

Item 9.01 Financial Statements, Pro Form Financial Information and Exhibits.
(c) Exhibits.

EXHIBITS

Exhibit	Description
99.1	Press Release dated January 29, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Renhuang Pharmaceuticals, Inc.

Date: January 29, 2007

By: /s/ Shaoming Li

Shaoming Li
Chief Executive Officer and President